New Zealand had a plan to be as rich as Australia. Here's how it failed
But instead of fostering a booming economy to rival that of its neighbour, the country faces rising unemployment, anaemic economic growth and a mass exodus of Kiwis across the Tasman Sea.
The outlook is so bleak that some in Wellington now joke that the government's next tagline should instead be to 'beat Fiji by 2050'.
For Don Brash, New Zealand's failed ambitions to match Australian incomes are especially frustrating.
He was appointed in 2009 to lead a high-profile, bipartisan task force charged with developing a strategy to close the income gap.
None of its 35 recommendations were adopted and the gap in GDP per capita has now grown, from a chasm of roughly $8,000 to $10,700.
'It was a case of missed opportunities,' said Dr Brash, who was governor of the Reserve Bank for 14 years and spent three years as leader of the opposition, for the New Zealand National Party, from 2003 to 2006.
'I think because we made some recommendations the government of the day did not like very much, they used the first opportunity they could to wind [the task force] up in 2011.
'I would've been relaxed about it if they had other plans to catch Australia. But they didn't… it just hasn't been a priority,' he told The Telegraph.
But reality is now hitting hard. Adjusting for purchasing power, GDP per person is about a third higher in Australia than in New Zealand – where the cost of living is high, unemployment has risen to a four-year high of 4.7 per cent and homelessness is rising.
New Zealand's economy, currently in recession, was the worst performing in the developed world last year, according to HSBC.
And so, despite New Zealand's reputation as an idyllic place to live and bring up a family, the net result is a mass exodus.
In 2024, 128,700 people left the Pacific nation of 5.3 million people, according to preliminary data, a figure roughly 40 per cent higher than the pre-pandemic average for this century.
While net migration was still 27,100 last year, it was a significant fall from 126,800 in 2023.
'Rather than seeing a brain exchange, we're seeing a brain drain,' said Paul Spoonley, a sociologist and emeritus professor at Massey University of New Zealand.
He added that it was no longer 'simply the 20-somethings going to live in Sydney or London for a few years to get work experiences, travel, and get away from Mum and Dad'. Now, skilled workers in their 30s, often with young families, are also leaving.
Stats NZ estimates that 56 per cent of Kiwis who left last year went 'across the ditch', enticed by better paid jobs, more generous pensions and an economy not in recession. In the last few years, Australia has made it even easier for New Zealanders to get passports and benefits.
'We have a soft labour market, so in the short term we're exporting some of our unemployment,' said Prof Spoonley. 'But the major impact is that we're losing our well-educated, skilled people. As the labour market begins to firm up in a few years, we're going to have a generational shortage [of workers].'
But he does not think the government is taking the situation seriously enough.
'We have adult children in their 30s, and when you look at their circle of friends, it's very obvious to see that a lot more have moved to Australia,' Prof Spoonley said.
He added: 'It seems to me we have a degree of complacency – I don't think we are seeing much of a debate about how we can improve our competitiveness with Australia. I think that's partly because the gap is so large, what could the government do to match it?'
So how did New Zealand lose pace compared to Australia in the first place?
In Dr Brash's mind, there are three key factors: Australia's mining boom, New Zealand's economic missteps and a level of economic productivity well below most of its peers.
'Australia has avoided a recession for the best part of 20 to 30 years, so in that sense, it has done well,' he said. 'There are various factors, mining being the most obvious – Australia has a very large amount of valuable mining assets, which have helped.'
But he added that New Zealand had failed to develop an ambitious strategy to boost its economy – ignoring a range of proposals included in the 'close the gap' taskforce's final report.
'We were recommending a more open policy to foreign investment and to reform the Resource Management Act – a cumbersome planning act which means if you want to build anything, there are substantial hoops,' Dr Brash said. 'But successful governments have kept that handbrake on development.'
He said this had contributed to a 'ridiculous' situation where, despite no lack of land, house prices were 'absolutely nuts'.
'Even a tent is unaffordable,' he joked. 'This is the result of serious policy failings.'
More broadly, Dr Brash bemoaned that recommendations to make New Zealand more attractive to foreign investment were sidelined.
'The corporate tax break is also no longer competitive – 28 per cent, which by Asian standards is high,' he said. 'We haven't made ourselves an attractive place for investment, so even when bright ideas do occur, people start businesses here [and] then sell them offshore.'
But the current situation has also been made worse by monetary policy in the last two or three years.
When New Zealand closed borders and provided an economic stimulus to protect against the coronavirus pandemic, this fanned inflationary pressures and pushed already high house prices to historic levels.
In response, and unlike Australia, the central bank increased interest rates and the government rapidly halted the fiscal spigots – triggering a recession.
This approach was dropped in August – partly when updated figures showed the economy had been growing more quickly than first thought in 2023 – but the bank's previously hawkish warnings had already hit households and businesses hard. Now the government has given up on achieving a budget surplus in the next five years.
'If we had perfect knowledge, perfect, accurate real-time data, then it would affect how we communicate,' Paul Conway, chief economist at the Reserve Bank of New Zealand, told Reuters. 'Unfortunately, it's not physics.'
But Dr Brash said it was never too late to turn the situation around – and he 'is more optimistic than most of my contemporaries' about the current outlook.
'The government ignored our recommendations in 2010/2011, and look where we are now. But that said, we still have an opportunity, there's always an opportunity in the present to do something about it.
'There are some moves afoot, [a] resource management act, foreign investment regime, some measures that make me optimistic that we are serious about improving productivity,' he said.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
28 minutes ago
- The Hill
Trump administration labels Australia move on beef imports ‘major' breakthrough
President Trump's administration labeled Australia's move to lift restrictions on U.S. beef imports as a 'major' breakthrough, arguing it will give more market access to American farmers and ranchers. Australia's Agriculture Minister Julie Collins announced that Australia's capital Canberra would ease biosecurity restrictions on U.S. beef imports after her department completed an assessment which has been conducted over the span of about five years. 'This decision has been purely based on science and a rigorous assessment by my department. Our biosecurity risk assessment process is very robust, and I have faith in the officials in my department to do this appropriately,' Collins told reporters on Wednesday. 'My department officials have been across in the US. They've gone along the entire supply chain, including in abattoirs and cutting houses in the U.S., to ensure the safety and security of any beef along the supply chain that may come into Australia, and my experts are assured and are confident that we have this assessment correct,' Collins added. Australia has permitted the import of cattle raised in the U.S. since 2019, although it has not allowed imports of U.S. beef from cattle raised in Mexico and Canada over mad cow disease risks. Secretary of Agriculture Brooke Rollins lauded the announcement as a 'major trade breakthrough' that would allow U.S. farmers greater access to the Australian market. 'American farmers and ranchers produce the safest, healthiest beef in the world. It's absurd that non-scientific trade barriers prevented our beef from being sold to consumers in Australia for the last 20 years,' Rollins said in a statement late Wednesday. 'Gone are the days of putting American farmers on the sidelines. This is yet another example of the kind of market access the President negotiates to bring America into a new golden age of prosperity, with American agriculture leading the way,' Rollins added. Trump hammered Australia's beef import restrictions in April when he announced that he would be imposing a 10 percent tariff on Canberra. 'Yet we imported $3 billion of Australian beef from them just last year alone. They won't take any of our beef,' Trump said at the time. 'They don't want it because they don't want it to affect their farmers and, you know, I don't blame them, but we're doing the same thing right now.'


Business Wire
3 hours ago
- Business Wire
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its entry into the Australian market by signing a new exclusive distribution agreement with Endotherapeutics Pty Ltd, a leading Australia-based distributor of cutting-edge medical devices, to bring the Cellvizio platform to Australian physicians. This strategic expansion comes as Mauna Kea experiences growing momentum for its CellTolerance application, prompting the company to open new geographic markets with strong growth potential. The three-year agreement grants Endotherapeutics the exclusive rights to distribute and promote the Cellvizio platform in Australia. As part of the market entry, a submission for Therapeutic Goods Administration (TGA) approval for the latest generation of Cellvizio products is underway. Mauna Kea Technologies has already been granted TGA clearance in the past and does not anticipate any hurdles in obtaining it again. The partnership will leverage the upcoming launch of the CellTolerance program with Professor Gerald Holtmann, MD, PhD, MBA, a leading Australian physician at Princess Alexandra Hospital in Brisbane, who is planning to acquire one Cellvizio for food intolerance applications. 'This technology brings hope of change for millions of patients suffering from food-related IBS symptoms,' commented Professor Holtmann. 'Cellvizio is truly unique in its ability to help identify the root causes of patient symptoms, enabling the creation of tailored diets. My entire team is excited to explore its full potential and improve the lives of our patients.' 'We're very pleased to partner with Mauna Kea Technologies to introduce Cellvizio to the vibrant Australian GI market,' stated Rob Curtin, Business Manager for GI at Endotherapeutics. 'The potential for Cellvizio and its key indications, particularly pancreatic cyst characterization and food intolerance detection is very significant.' Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, added: "We are thrilled to partner with Endotherapeutics, a premier distributor of cutting-edge medical devices and a trusted partner with deep roots in the Australian healthcare system. This partnership marks a key milestone in our international expansion strategy. As we see good momentum in the adoption of our platform, particularly for CellTolerance, we are taking key initiatives to expand our market reach in territories with strong growth potential.' *** About Endotherapeutics Pty Ltd Endotherapeutics is a leading Healthcare Technologies distributor serving customers across Australia and New Zealand, headquartered in Sydney, Australia. Endotherapeutics' mission is to improve healthcare and achieves this by supplying innovative healthcare solutions with the highest levels of service and support. To find out more, visit About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.


Newsweek
3 hours ago
- Newsweek
List of Places Where Tesla Faces Legal Action Over Self-Driving Cars
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Tesla, headed by CEO Elon Musk, has come under increasing legal scrutiny worldwide over its self-driving technology, with lawsuits and regulatory actions unfolding in France, Australia, Florida, and California. Many of the cases share a common theme of criticizing Tesla's advertising, with lawyers saying that the company's claims of "autonomous vehicles" fail to live up to reality. Newsweek contacted Tesla for more information on the legal action via email. The Context Tesla's global sales have struggled in 2025, with developing foreign competition further threatening its leading position in key markets, and backlash against CEO Elon Musk's role in President Donald Trump's administration resulting in protests and boycotts of the company's vehicles. The legal challenges across the world mean Tesla has further issues to deal with, despite Musk's departure from the White House. France In France, the government has ordered Tesla to fix a series of violations over deceptive business practices, with the company facing daily fines of $58,000 if it fails to comply. French regulators determined that Tesla's "autonomous driving" features do not meet the standard implied by the company's marketing, and said that the company misled buyers by overstating the power of its autonomous driving technology. A Tesla electric car retail store and company brand logo sign at night, Wuhan, China, May 2nd 2024. A Tesla electric car retail store and company brand logo sign at night, Wuhan, China, May 2nd 2024. Getty Images Australia Thousands of Australian Tesla owners have joined a class action alleging "phantom braking" and misleading claims about the vehicles' capabilities and performance. Plaintiffs describe repeated, sudden, and unexplained braking events while using Tesla's Autopilot system, with some incidents leading to collisions or dangerous situations. "Drivers have reported feeling completely terrified when their vehicles have braked suddenly and it has led in some cases to collisions," said class action lawyer Rebecca Jancauskas in an interview in June. "We've had many reports of people who registered for this class action, telling us that they've been driving with their hands on the vehicle, fully alert, and these issues have occurred nonetheless." Florida In Miami, Florida, a federal jury trial is underway following a fatal 2019 crash involving a Tesla Model S using its Autopilot system. Plaintiffs claim Tesla exaggerated the abilities of its self-driving features, encouraging drivers—like George McGee, who admitted distraction at the wheel—to become over-reliant on the technology. The crash led to the death of Naibel Benavides Leon and severe injury to her companion. George McGee said in court, "I trusted the technology too much," acknowledging he took his attention off the road because of his confidence in the autopilot. The trial, overseen by U.S. District Judge Beth Bloom, is expected to set a precedent for how driver-assistance technologies are marketed and what obligations manufacturers bear. California The California Department of Motor Vehicles has filed a lawsuit seeking to halt Tesla sales and manufacturing in the state for at least 30 days. The Department accuses Tesla of making false and misleading claims about its autopilot and full self-driving capabilities, alleging the features are advertised as being more autonomous than they actually are. Attorney General Rob Bonta said in a statement, "These labels and descriptions represent specifically that respondent [Tesla]'s vehicles will operate as autonomous vehicles, which they could not and cannot do". What Happens Next The outcomes of these legal actions may have wide-reaching implications for Tesla and the broader self-driving automotive sector. In California, the DMV's lawsuit could result in a month-long suspension of Tesla's sales and manufacturing, potentially influencing how all automakers market advanced driver assistance systems.